Adalimumab is associated with reduced skin pain in patients with moderate to severe hidradenitis suppurativa (HS): Results from the first 12 weeks of PIONEER II - 09/05/15
Alexandra B. Kimball, MD, MPH, Harvard Medical School, Boston, MA, United States; Brett Pinsky, PhD, AbbVie, North Chicago, IL, United States; Murali Sundaram, MBA, PhD, AbbVie, North Chicago, IL, United States; Ziqian Geng, PhD, AbbVie, North Chicago, IL, United States; Martin Okun, MD, PhD, AbbVie, North Chicago, IL, United States; Yanjun Bao, PhD, AbbVie, North Chicago, IL, United States
Le texte complet de cet article est disponible en PDF. Funding statement: Design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. All authors contributed to the development of the publication and maintained control over the final content. |
Vol 72 - N° 5S1
P. AB39 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?